Ventricular tachycardia, which begins in the heart’s lower chambers, can lead to sudden cardiac arrest if sustained. 

Patients are treated with medication or may receive an implanted defibrillator to deliver pacing therapy or shocks to restore normal heart rhythm. Catheter ablation approaches to treat the condition have remained “suboptimal,” Medtronic noted.

The company’s Affera and Sphere-9 technologies combine mapping with pulsed field and radiofrequency ablation to treat irregular heartbeats including atrial fibrillation, a common arrhythmia that raises the risk of stroke. Medtronic’s pulsed field ablation sales have grown quickly as physicians have embraced the treatment approach, and companies including Boston Scientific, Johnson & Johnson and Abbott are all battling for market share in P